Ensysce Biosciences, Inc. (ENSC) Submits CY200 Phase 2a Protocol to UK MHRA

Ensysce Biosciences submitted a Phase 2a protocol to the UK MHRA for CY200 in CRPS Type 1, a randomized, placebo-controlled proof-of-concept study planned in the UK.Material DetailsContext by AI AnalystThis is an early clinical milestone signaling execution on a newly acquired neuroplastigen asset…